New national guidelines on hypertension: A summary for dentistry

Journal of the American Dental Association

Volumn 135, Issue 5, 2004, Pages 576-584

  Herman, Wayne W ^a   Konzelman Jr , Joseph L ^a   Prisant, L Michael ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CEVIMELINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; LABETALOL; METHYLDOPA; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PILOCARPINE; PROPRANOLOL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE REGULATION; BURNING MOUTH SYNDROME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONSULTATION; COUGHING; DENTAL CARE; DENTISTRY; DIET; DISEASE CLASSIFICATION; DISEASE SEVERITY; GINGIVA OVERGROWTH; GOVERNMENT; HEALTH CARE; HEALTH CARE ORGANIZATION; HEALTH PRACTITIONER; HEALTH PROMOTION; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; LICHENOID; LIFESTYLE; MEDICAL EXPERT; MEDICAL INFORMATION; ORTHOSTATIC HYPOTENSION; PATIENT CARE; PATIENT MONITORING; PHYSICIAN; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE; SYSTOLIC BLOOD PRESSURE; TASTE DISORDER; TREATMENT INDICATION; UNITED STATES; XEROSTOMIA;

EID: 2642525918     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2004.0244     Document Type: Article

References (74)

1. U.S. Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Available at: "www.nhlbi.nih.gov/guidelines/hypertension/index.htm". Accessed July 17, 2003.
2. Chobanian AV, Bakris GL, Black HR, et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC7 report (published correction appears in JAMA;290[2]:197). JAMA 2003;289:2560-72.
3. Chobanian AV, Bakris GL, Black HR, et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
4. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003;290(2):199-206.
5. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002;287:1003-10.
6. Gordy FM, Le Jeune RC, Copeland LB. The prevalence of hypertension in a dental school patient population. Quintessence Int 2001;32:691-5.
7. American Dental Association Council on Dental Health. Suggestions for dentists on participating in the National High Blood Pressure Education and Detection Program. JADA 1977;94(6):1190.
8. Hypertension detection and control: importance stressed at Dental Leadership Conference on High Blood Pressure. JADA 1976;93(1):48-50.
9. The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1988;148(5):1023-38.
10. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153(2):154-83.
11. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (published correction appears in Arch Intern Med 1998;158:573). Arch Intern Med 1997;157(21):2413-46.
12. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265:3255-64.
13. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997;278:212-6.
14. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (published correction appears in Lancet 2003;361:1060). Lancet 2002;360(9349):1903-13.
15. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345:1291-7.
16. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001;358(9294):1682-6.
17. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med 1997;157:657-67.
18. He J, Whelton PK, Appel LJ, Charleston J, Klag MJ. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 2000;35:544-9.
19. Sacks FM, Svetkey LP, Vollmer WM, et al.; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001;344:3-10.
20. Vollmer WM, Sacks FM, Ard J, et al.; DASH-Sodium Trial Collaborative Research Group. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med 2001;135:1019-28.
21. Chobanian AV, Hill M. National Heart, Lung, and Blood Institute Workshop on Sodium and Blood Pressure: a critical review of current scientific evidence. Hypertension 2000;35:858-63.
22. Kelley GA, Kelley KS. Progressive resistance exercise and resting blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2000;35:838-43.
23. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002;136:493-503.
24. Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2001;38:1112-7.
25. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997;336:1117-24.
26. Cushman WC, Ford CE, Cutler JA, et al.; ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002;4:393-404.
27. Mitka M. Hypertension experts recommend new focus on the systolic reading. JAMA 2000;284:1638-9.
28. Arauz-Pacheco C, Parrott MA, Raskin P; American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2003;26(supplement 1):S80-2.
29. National Kidney Foundation, Kidney Disease Outcome Quality Initiative Advisory Board. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002;39(2)(supplement 1):S1-246.
30. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356(9246):1955-64.
31. Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 2000;35:539-43.
32. Cowper TR, Terezhalmy GT. Pharmacotherapy for hypertension. Dent Clin North Am 1996;40:585-610.
33. Little JW. The impact on dentistry of recent advances in the management of hypertension. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:591-9.
34. Jones DW, Frohlich ED, Grim CM, Grim CE, Taubert KA. Mercury sphygmomanometers should not be abandoned: an advisory statement from the Council for High Blood Pressure Research, American Heart Association. Hypertension 2001;37(2):185-6.
35. Jones DW, Appel LJ, Sheps SG, Roccella EJ, Lenfant C. Measuring blood pressure accurately: new and persistent challenges. JAMA 2003;289:1027-30.
36. Muzyka BC, Glick M. The hypertensive dental patient. JADA 1997;128:1109-20.
37. Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med 1977;297:845-50.
38. Ashton CM, Petersen NJ, Wray NP, et al. The incidence of perioperative myocardial infarction in men undergoing noncardiac surgery. Ann Intern Med 1993;118:504-10.
39. Lette J, Waters D, Bernier H, et al. Preoperative and long-term cardiac risk assessment: predictive value of 23 clinical descriptors, 7 multivariate scoring systems, and quantitative dipyridamole imaging in 360 patients. Ann Surg 1992;216:192-204.
40. Eagle KA, Berger PB, Calkins H, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery. Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 2002;105:1257-67.
41. Fleisher LA. Preoperative evaluation of the patient with hypertension. JAMA 2002;287:2043-6.
42. Dionne RA, Goldstein DS, Wirdzek PR. Effects of diazepam premedication and epinephrine-containing local anesthetic on cardiovascular and plasma catecholamine responses to oral surgery. Anesth Analg 1984;63:640-6.
43. Goulet JP, Perusse R, Turcotte JY. Contraindications to vasoconstrictors in dentistry, part III: pharmacologic interactions. Oral Surg Oral Med Oral Pathol 1992;74:692-7.
44. Perusse R, Goulet JP, Turcotte JY. Contraindications to vasoconstrictors in dentistry, part I: cardiovascular diseases. Oral Surg Oral Med Oral Pathol 1992;74:679-86.
45. Glick M. New guidelines for prevention, detection, evaluation and treatment of high blood pressure. JADA 1998;129:1588-94.
46. Bader JD, Bonito AJ, Shugars DA. A systematic review of cardiovascular effects of epinephrine on hypertensive dental patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93:647-53.
47. Riley CK, Terezhalmy GT. The patient with hypertension. Quintessence Int 2001;32:671-90.
48. Yagiela JA. Injectable and topical local anesthetics. In: Ciancio SG, ed. ADA Guide to dental therapeutics. 2nd ed. Chicago: ADA Publishing; 2000:1-16.
49. Knoll-Kohler E, Frie A, Becker J, Ohlendorf D. Changes in plasma epinephrine concentration after dental infiltration anesthesia with different doses of epinephrine. J Dent Res 1989;68:1098-101.
50. Navazesh M. How can oral health care providers determine if patients have dry mouth? JADA 2003;134:613-20.
51. Ship JA, Pillemer SR, Baum BJ. Xerostomia and the geriatric patient. J Am Geriatr Soc 2002;50:535-43.
52. Guggenheimer J, Moore PA. Xerostomia: etiology, recognition and treatment. JADA 2003;134:61-9.
53. Ellis JS, Seymour RA, Steele JG, Robertson P, Butler TJ, Thomason JM. Prevalence of gingival overgrowth induced by calcium channel blockers: a community-based study. J Periodontol 1999;70(1):63-7.
54. Prisant LM, Herman W. Calcium channel blocker induced gingival overgrowth. J Clin Hypertens 2002;4(4):310-1.
55. Miranda J, Brunet L, Roset P, Berini L, Farre M, Mendieta C. Prevalence and risk of gingival enlargement in patients treated with nifedipine. J Periodontol 2001;72:605-11.
56. Tavassoli S, Yamalik N, Caglayan F, Caglayan G, Eratalay K. The clinical effects of nifedipine on periodontal status. J Periodontol 1998;69(2):108-12.
57. Thomason JM, Seymour RA, Ellis JS, et al. Determinants of gingival overgrowth severity in organ transplant patients: an examination of the role of HLA phenotype. J Clin Periodontol 1996;23:628-34.
58. Kunimatsu K, Ozaki Y, Aoki Y, Kato I. Possible roles of medullasin in nifedipine-induced human gingival overgrowth. Arch Oral Biol 1996;41(1):111-5.
59. Williams BG. Oral drug reaction to methyldopa: report of a case. Oral Surg Oral Med Oral Pathol 1983;56:375-7.
60. Firth NA, Reade PC. Angiotensin-converting enzyme inhibitors implicated in oral mucosal lichenoid reactions. Oral Surg Oral Med Oral Pathol 1989;67:41-4.
61. Robertson WD, Wray D. Ingestion of medication among patients with oral keratoses including lichen planus. Oral Surg Oral Med Oral Pathol 1992;74:183-5.
62. Brown RS, Krakow AM, Douglas T, Choksi SK. 'Scalded mouth syndrome' caused by angiotensin converting enzyme inhibitors: two case reports. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;83:665-7.
63. Becker DE. The autonomic nervous system and related drugs in dental practice, part II: adrenergic agonists and antagonists. Compendium 1988;9:772-4,776,778-80.
64. Sugimura M, Hirota Y, Shibutani T, et al. An echocardiographic study of interactions between pindolol and epinephrine contained in a local anesthetic solution. Anesth Prog 1995;42(2):29-35.
65. Replogle K, Reader A, Nist R, Beck M, Weaver J, Meyers WJ. Cardiovascular effects of intraosseous injections of 2 percent lidocaine with 1:100,000 epinephrine and 3 percent mepivacaine. JADA 1999;130:649-57.
66. Yagiela JA. Adverse drug interactions in dental practice: interactions associated with vasoconstrictors. JADA 1999;130:701-9.
67. Meechan JG. Plasma potassium changes in hypertensive patients undergoing oral surgery with local anesthetics containing epinephrine. Anesth Prog 1997;44(3):106-9.
68. de Leeuw PW. Nonsteroidal anti-inflammatory drugs and hypertension. The risks in perspective. Drugs 1996;51(2):179-87.
69. Ivanhoe JR, Cibirka RM, Lefebvre CA, Parr GR. Dental considerations in upper airway sleep disorders: a review of the literature. J Prosthet Dent 1999;82:685-98.
70. Schmidt-Nowara W, Lowe A, Wiegand L, Cartwright R, Perez-Guerra F, Menn S. Oral appliances for the treatment of snoring and obstructive sleep apnea: a review. Sleep 1995;18:501-10.
71. Leung RS, Bradley TD. Sleep apnea and cardiovascular disease. Am J Respir Crit Care Med 2001;164:2147-65.
72. Dart RA, Gregoire JR, Gutterman DD, Woolf SH. The association of hypertension and secondary cardiovascular disease with sleep-disordered breathing. Chest 2003;123(1):244-60.
73. Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study (published correction appears in JAMA 2002;288:1985). JAMA 2000;283:1829-36.
74. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000;342:1378-84.